CENTOGENE

THE RARE DISEASE COMPANY

Diagnose.
Understand.
Treat.

Investor & Analyst Event
June 2021

Speakers and agenda

1. Strategy Update
   Andrin Oswald | CEO

2. Building the Leading Bio/Databank in Rare Diseases
   Bettina Goerner | CDO

3. Superior Genomics Insights for Clinical Diagnostics
   Max Schmid | CCO Dx, Peter Bauer | CGO


4. Enabling Differentiated Orphan Drug Development
   Michael Motz | CCO Pharmaceuticals, Justin Bingham | SVP Business Development


5. Unlocking the Complexity of Rare Diseases With Multiomics
   Volkmar Weckesser | CIO, Claudia Cozma | VP Biomarker , Philip Lambert | CSO



6. Finance Priorities and Process Optimization
   Rene Just | CFO[1]

1 To be appointed at upcoming AGM

Safe harbor statement

This presentation has been prepared by Centogene N.V. (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology, such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project" or "expect," "may," "will," "would," "could" or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on April 15, 2021 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

1. Strategy Update

If it is rare, I care

Andrin Oswald, M.D.

Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

ICRC

McKinsey & Company

NOVARTIS

BILL & MELINDA GATES *foundation*

Why rare?

We focus on rare diseases, one of the highest unmet patient need areas remaining and a large and growing market

~350 Million people affected by rare genetic diseases, ~90% undiagnosed.

<5% of rare diseases have meaningful therapies, ~7,000 hereditary rare diseases identified.

Market is accelerating in terms of sales as well as R&D spend

Market for therapies and diagnostics in rare diseases is growing

Orphan Drug Market

Source: EvaluatePharma® Orphan Drug Report 2019

Precision medicine at the focal point of technology and therapy trends

Enabled by access to real world patient data

AI and big data empowering the analysis of complex datasets

Precision medicine for genetically driven diseases is enabled by technological development in recent years.

Breakthrough new therapeutic platforms gaining ground

e.g., Gene, RNA, and cell therapy, CRISPR

Multiomics tools accelerating the medical revolution

Mission

We are a data-driven rare disease company that unlocks the complexities of patients' biology to diagnose, understand, and treat rare diseases.

Our goal is to enable the cure of 100 rare diseases in 10 years.

What makes CENTOGENE unique?

Bridging the gap between strong technology trends and new therapy platforms

Precision medicine for genetically driven diseases is in our DNA.

Leading genomic rare disease **expertise**

Strong **brand** in scientific and medical community

Largest **Bio/Databank** with samples of rare genetic diseases

Global **footprint** incl. many countries where rare genetic diseases are highly prevalent

Strong, established **physician** and customer network

Unique and fast-growing Bio/Databank for rare diseases

Every diagnosed patient improves our position to enable discovery, development, and translation



Breadth of Bio/Databank

Geographical diversity of samples allows us to generate unique insights

Depth of Bio/Databank

Insights into genotype/phenotype associations

Connecting patients to develop disease-specific knowledge

Full disease models driving new therapies

1 Illustrative graphs. Metrics dependent on exact definition incl. variant classification.

Leading data-driven insights creator in rare diseases

Peer group of data-driven insights companies



Reflecting internal assessment. Legend: ✔ fully, ✔ partially, ✕ minor/none

Newly-formed leadership team focused on value creation

Building the Leading Bio/Databank in Rare Diseases
Bettina Goerner | Chief Data Officer

Superior Genomics Insights for Clinical Diagnostics
Max Schmid | CCO Dx, Peter Bauer | Chief Genomic Officer


Enabling Differentiated Orphan Drug Development
Michael Motz | CCO Pharmaceuticals, Justin Bingham | SVP Business Development


Unlocking the Complexity of Rare Diseases With Multiomics
Volkmar Weckesser | CIO, Claudia Cozma | VP Biomarker , Philip Lambert | CSO



Finance Priorities and Process Optimization
Rene Just | CFO[1]

1 To be appointed at upcoming AGM

CENTOGENE business model and strategic value creation



Tremendous future value potential for CENTOGENE by enabling orphan drug development

Future potential of capturing share of orphan disease market

CENTOGENE Key levers

- Superior patient diagnostic insights
- Accelerate clinical trials
- De-risk clinical trials
- Increase chance of approval
- Maximize re-imbursement



~100 diseases**

Total estimated addressable future rare disease market 2031*

Estimated annual royalty revenue potential ***

1% ≈ $ 0.5 billion
2% ≈ $ 1.0 billion
3% ≈ $ 1.5 billion
4% ≈ $ 2.0 billion
5% ..

*Above represents CENTOGENE's internal estimates based on the total orphan drug market of $156bn in 2021 by Evaluate Pharma® February 2020, estimating the addressable non-oncology rare disease market at ~$70bn in 2021 and applying the CAGR of 11% for 10 years, leading to an estimated future rare disease market potential of ~$200bn in 2031.
**Future market potential estimate based on peak sales of $500M per orphan drug for 100 diseases.
*** Estimated annual revenue potential from potential future royalty share calculated on the basis of the estimated future rare disease market potential 2031.

2. Building the Leading Bio/Databank in Rare Diseases

Samples from all over the world proceed along our cutting-edge value chain

Data capture, processing, and analysis is fully owned by CENTOGENE and is optimized for value generation



What data do we have?

Our multi-modal data is rich with clinical and biological insights



Biomaterial & Extracts

Dried Blood Spots cards

Sociodemographic Information

Age, geography

Clinical Information

For Parkinson's: Age of onset, motor and other symptoms, comorbidities, treatment, etc.

Multiomic Data

For Parkinson's: Parkinson's core genes and panel; Whole Genome Sequencing & biomarker data

Our data from genetically diagnosed patients covers >2,500 diseases

Strength in metabolic & neurological (CNS) disorders



Hierarchical data structure of genetically diagnosed patients and related diseases

Each color represents each **disease group**. Each subcategory within the same color represents the specific disease.

The size of the subcategory corresponds to the **proportion of patients** in this disease group.

Our growing Bio/Databank enables key use cases with data breadth & depth



Clinical Dx

Patient Identification

Clinical Trial Support

Drug Discovery & Development

>2,500
rare diseases diagnosed to date

>31 million
unique variants

>300
disease cohorts with at least 20 patients

>400,000
biosamples

20,000
physicians in our network w/ contact in last 5 years

Progress full disease models
each ~100-500 diagnosed patients with full-omics profile and ~10-20 cell lines for the cellular model in growing number of full disease model

We manage our Bio/Databank flywheel proactively to grow best-in-class datasets for diseases

Enrich with

Multiomics

Cellomics

Third-party data



Increase

Samples

Clinical information

Longitudinal data

Consent

Full genomes

for key diseases

3. Superior Genomics Insights for Clinical Diagnostics

CENTOGENE business model and strategic value creation



Superior genomic insights for diagnosing rare diseases

We are a recognized worldwide leader in rare disease diagnostics with 15 years of experience and a unique Bio/Databank

Our Unique Strength

Our **distinctive product offering** is centered around high quality genetic testing to diagnose rare genetic diseases

We have a **strong presence** in and good access to countries with a **high prevalence of rare diseases**

Our CentoCard® provides **easy logistics** for central testing

Our diagnostic solutions are powered by our unique, proprietary Bio/Databank – enabling us to generate **best-in-class medical insights**

We are capitalizing on the increasing shift to Next Generation Sequencing as a first-line tool in clinical practice and **rapid market growth**

CENTOGENE has been an early proponent of Dx Whole Genome Sequencing

Scientific developments are award-winning

"Successful application of genome sequencing in a diagnostic setting: 1,007 index cases from a clinically heterogeneous cohort"

2020 EJHG
Reader's Choice

European Journal of Human Genetics

2020 EJHG
Editor's Choice

Genotype and phenotype connections driving diagnostic yield

A Dx success story in Pakistan

"Genomic testing in 1,019 individuals from 349 families results in high diagnostic yield and clinical utility" npj | genomic medicine



61.3%

GENETIC DIAGNOSIS (P/LP VARIANTS)

51.9%

of diagnosed patients have new or adjusted treatment implemented

12

Scientific Impact: 12 novel candidate genes in 66 cases with no genetic diagnosis

Leveraging Bio/Databank to unlock new disease insights

Driving innovation and insights with research

“Combining exome/genome sequencing with data repository analysis reveals novel gene-disease associations for a wide range of genetic disorders”

Genetics inMedicine nature



6

detected novel gene-disease associations based on ~40 patients from 13 countries

31

candidate genes which had little published evidence and no registered OMIM phenotype

Global footprint in Clinical Diagnostics

Country ranking according to number of commercial orders received*



>100 countries served

*Clinical Diagnostics commercial orders received 2012 to April 2021, order status "cancelled" excluded - Map for illustration purposes only

Clinical Diagnostics addressable market

with CAGR of

~10%

Source: Internal CENTOGENE 2020 estimates; 2018-2021 CAGR based on CENTOGENE market model

Clinical Diagnostics growth

Return to pre-pandemic double digit growth in Clinical Diagnostics expected in 2021

Number of commercial analysis performed*



Goal:
Outperforming the market

*Commercial samples only - excl. COVID-19 business, rounded

Best-in-class insights based on superior technology

New CentoXome® with improved design and insights based on CENTOGENE's unique rare disease-centric Bio/Databank launched June 2021

Up to 20% Increased Diagnostic Yield

NEW CentoXome®

~20,000 genes

≥ 98.0% ≥ 20x

~8,000 clinical genes

≥ 99.5% ≥ 20x

OMIM® HGMD®

CENTOGENE

Non-coding pathogenic variants

HGMD® ClinVar

CENTOGENE

Mitochondrial genome

37 genes

Innovation to sustain our leadership position in Clinical Diagnostics

CENTOGENE is continuing to innovate in Clinical Diagnostics based on its unique capabilities and expertise



CentoCloud®

CentoMetabolome & Multiomics

4. Enabling Differentiated Orphan Drug Development

CENTOGENE's core business model for pharma

Data is THE key to creating solutions in rare diseases

Differentiation

Unique **understanding of the molecular characteristics** of rare diseases

Accumulation of **real-world patient data in** the CENTOGENE Bio/Databank

Ability to **correlate molecular characteristics** and patient genotypes with the respective **phenotypes**

Discovery of **differentiated treatments** for patients with rare diseases in **collaboration** with pharma



CENTOGENE's unique value proposition to pharma

Turn data-centric insights into tangible assets and value for pharma

Insight's Commercialization

Commercialization

Patient Identification

- Enable patient finding for the right treatment

Clinical Development

Clinical Trial Support

- Enable and accelerate recruitment
- Biomarkers as clinical endpoints
- Patient stratification

Fueling the Bio/Databank

$

$$

Disease Offering

Research

Drug Discovery and Development

- Biomarker IP
- Composition of matter IP
- Differentiated treatments

$$$$$

Capturing increasing value in fast growing multi-billion rare disease market

Rare disease therapeutics CAGR +11% propelled by Orphan Drug Act



Above represents Centogene internal estimates based on total orphan drug market of $156bn in 2021 by Evaluate Pharma® February 2020
* Addressable non-oncology rare disease market; Company estimate.

Pharma is already buying into our concept of enabling precision medicine

Generate data and insight exemplified in our recent deals

Our unique position …

Understand the molecular characteristics of Parkinson's disease



Identify patients with frontal temporal dementia mutations

Turning these insights into precision medicine

… led to pharma engagements

DENALI

ROPAD* Study to genotype up to 12,500 patients with Parkinson's disease globally

ALECTOR THERAPIES TO REMEMBER

EFRONT* Study to determine prevalence of *GRN* in >3,000 frontotemporal dementia patients across Europe

evotec

Combining external hit discovery with CENTOGENE´s novel disease insights to produce IND enabling therapies

Uniquely positioned to further leverage patient identification and stratification with biomarker pipeline

Biomarker pipeline for future value generation



1 Discovery | 2 Prototype | 3 CLIA LDT | 4 Diagnostics | 5 Clinical Trials | 6 R&D activity | 7 Partner

Integration of data, AI, and multiomics leads to a new disease offering for Pharma

Enable differentiated drug discovery and development



Integrating key assets and capabilities allows the path of translational precision medicine for rare diseases to be addressed.

5. Data-Driven Insights With Multiomics

CENTOGENE business model and strategic value creation



Genomics is important, but often not sufficient for a precise diagnosis

Biomarkers support the genetic diagnosis in complex or unclear cases

Genomic Diagnosis

Two patients have the same genetic mutation leading to the same diagnosis.

Same disease, but different clinical picture: one manifests early, and the other does not.



Potential Schemes and Criteria for Stratification

56x the same genetic mutation but different disease severity

Homozygous variant for GBA p.N409S



Biomarker data correlates difference in disease severity



Up to **25%** higher diagnostic yield for Gaucher/ Parkinson's cases compared to genomic data only

*osteolytic lesions, osteonecrosis, pathologic fracture, bone crisis, hepatosplenomegaly, thrombocytopenia

Genomics is important, but often not sufficient for a precise diagnosis

Biomarkers support the genetic diagnosis in complex or unclear cases

Genomic Diagnosis

Two patients have the same genetic mutation leading to the same diagnosis.

Same disease, but different clinical picture: one manifests early, and the other does not.





Multiomic Diagnosis

Two patients have the same genetic mutation, but different disease development

Multiomic analytical insights lead to better disease models and thus to more precise medicine

How we achieve this advantage

Multiomic analysis approach to help end the diagnostic odyssey of patients with rare genetic diseases

Metabolites – The Ultimate Readout

Closest

Metabolites are downstream products of the genome and a proxy to the functional phenotype of the cell

Unique

Alterations of metabolites can be observed even when alterations of proteins and transcripts are not detectable.

Dynamic

Metabolites are quantitatively measured – not black or white as a variant – and mirror the dynamic development of the disease as well as different manifestations.



CentoMetabolome

enables efficient identification of differences (single molecules and complex signatures) between metabolomic profiles of patient and control cohorts.



Value of Biomarkers

- Biomarker for diagnostics: -90% costs in the lab and higher diagnostic yield
  (e.g., +10%/+25% increased yield for complex Parkinson's/ Gaucher cases)
- Patient identification / diagnosis
- Clinical trial support
- Drug discovery and development

New value creation with the CentoMetabolome platform

CentoMetabolome drives further value adding use cases on metabolomic data

FRIEDREICH-ATAXIA

Identification of 11 potential biomarkers, which passed all quality filters and were confirmed with TQMS



HEREDITARY ANGIOEDEMA

Ongoing analysis:

Two biomarker candidates passed first confirmation steps; several others in evaluation inclusive attack biomarkers



Artificial Intelligence as an enabling link along the value chain

AI tools allow us to unlock multiomic data

Use the potential of AI…

Discovery of patterns and interdependencies in high-dimensional multiomic data

Integration of CENTOGENE's patient-based data with public data

Analysis of patient-based data through visualization in disease context



Integrated workbench for scientific multiomic workflows

…to identify new genes, genetic modifiers, and pre-targets

Multiomic Interdependencies

Use mutations and measurable effects on the metabolome to identify new pathways

Integration With Public Data

Enable complex insights that take complete biological knowledge on genes, metabolites, and interactions into account.

Visualization

Enable medical experts to better understand disease pathways of specific cohorts

What can we do with a multiomic diagnosis?

Profiles gathered in Biobanks represented in cell-based model (e.g., Gaucher)

Bio/Databank

- 80 Gaucher patients derived fibroblasts
- >80 Gaucher carriers derived fibroblasts

Predictive Disease Model (cell-based model)

- Patient-derived macrophages
- Mimicking closely patient pathophysiology
- Generating omics data for new target discovery
- Validating targets/compounds



CENTOGENE Bio/Databank

- Large patient cohorts
- Large data sets
  - Genetically defined patient
  - Specific Biomarker
  - Metabolomics data
- Diagnostic biomarker

iPSC Bio/Databank

- >15 Gaucher patients IPSC lines
- Extensively quality controlled

We have done this for two diseases, Gaucher and NPC

Severity Measure for Gaucher



Severity Measure for NPC



What is the potential?

iPSC technology as a tool for drug development in rare diseases

Potential: Develop Drugs for Diseases

Selection From Bio/Databank

- Patients derived fibroblasts
- Carriers derived fibroblasts

Predictive Disease Model (cell-based model)

- Patient-derived macrophages
- Mimicking closely patient pathophysiology reducing
- Generating omics data for new target discovery
- Validating targets/compounds

Lead Optimization

- Extensive optimization/ profiling from hit to lead compound with evotec



CENTOGENE Bio/Databank

- Large patient cohorts
- Large data sets
  - Genetically defined patient
  - Specific Biomarker
  - Metabolomics data

iPSC Bio/Databank

- Patients IPSC lines
- Extensively quality controlled

Drug Screening and Validation

- Screening 250K compounds with evotec
- Validating top hits in patient derived macrophages

Current focus diseases for full disease models

Fabry disease

Niemann-Pick disease

Gaucher disease

Parkinson's disease

Metabolic

Gaucher Disease

Niemann-Pick Type C - Disease

Neurological

Parkinson's Disease



6. Finance Priorities and Process Optimization

Introducing the new CFO

René Just

Let me introduce myself.

Purpose
Unique focus on rare diseases

Properties
Growing Bio/Databank

Potential
in bringing precision medicine to rare diseases

Together we will drive results

Our priorities

Organization

Supporting the organization in realizing the strategic plan

Processes

Improving the reporting and closing cycles

Transparency

Creating greater transparency

Capital

Deploy capital efficiently with focus on core business

Growth

Supporting the growth plan

Values

Help articulating and setting organizational values



Recent momentum indicates recovery of core business

Maintaining and building leadership in rare disease diagnostics

Pharma

Contracts signed in 2021

Takeda	Extension signed in Q1	DENALI THERAPEUTICS	Extension signed in Q1	ALECTOR THERAPIES TO REMEMBER	New contract signed in Q2

Diagnostics

Sample Order Intake value in percent*



* Reflects quarterly average of value of weekly sample order intakes for diagnostic analysis in the Clinical Diagnostics segment relative to Q1 2020. The value for Q1 2021 is based on the first 12 weeks of the year 2021.
** The value for Q2 2021 reflects calendar weeks 13 to 21.

Recovery in Core Business

Dx revenue Q1 2021 above Q4 2020

Average weekly sample order intake value in Q2 2021 above same period prior year **

Extension of Takeda and Denali collaboration

New Alector contract regarding frontotemporal dementia

>25,000 patients added to rare diseases-centric Bio/Databank

Summary

Tremendous future value potential for CENTOGENE by enabling orphan drug development

Future potential of capturing share of orphan disease market

CENTOGENE Key levers

- Superior patient diagnostic insights
- Accelerate clinical trials
- De-risk clinical trials
- Increase chance of approval
- Maximize re-imbursement



~100 diseases**

Total estimated addressable future rare disease market 2031*

Estimated annual royalty revenue potential ***

1% ≈ $ 0.5 billion
2% ≈ $ 1.0 billion
3% ≈ $ 1.5 billion
4% ≈ $ 2.0 billion
5% ..

*Above represents CENTOGENE's internal estimates based on the total orphan drug market of $156bn in 2021 by Evaluate Pharma® February 2020, estimating the addressable non-oncology rare disease market at ~$70bn in 2021 and applying the CAGR of 11% for 10 years, leading to an estimated future rare disease market potential of ~$200bn in 2031.
**Future market potential estimate based on peak sales of $500M per orphan drug for 100 diseases.
*** Estimated annual revenue potential from potential future royalty share calculated on the basis of the estimated future rare disease market potential 2031.

Investment summary

Empowering new management team to execute on mission

Clear **focus on core rare disease business**

Return to pre-pandemic sales growth trajectory in core business segments

Tracking Our Mid-Term Progress

- **Revenue** in Dx and Pharma segment to **outgrow the market**
- Reach **1 million patients in Bio/Databank**
- **Grow physician network** of active users
- Reach **10 full disease models**
- **Sign 2-4 strategic partnership deals** towards enabling therapy development

Goal of enabling cure of **100 rare diseases in 10 years**

THANK YOU FOR YOUR ATTENTION.

Q&A